bitter melon
Selected indexed studies
- Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. (Complement Ther Med, 2020) [PMID:32951763]
- Bitter melon: antagonist to cancer. (Pharm Res, 2010) [PMID:20198408]
- Bitter melon: a panacea for inflammation and cancer. (Chin J Nat Med, 2016) [PMID:26968675]
_Worker-drafted node — pending editorial review._
Connections
bitter melon helps
Sources
- Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. (2020) pubmed
- Bitter melon: antagonist to cancer. (2010) pubmed
- Bitter melon: a panacea for inflammation and cancer. (2016) pubmed
- Bitter melon (Momordica charantia): a review of efficacy and safety. (2003) pubmed
- The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy. (2023) pubmed
- Emerging Antitumor Activities of the Bitter Melon (Momordica charantia). (2019) pubmed
- Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. (2016) pubmed
- The effects of bitter melon (Momordica charantia) on anthropometric indices in adults: A systematic review and meta-analysis of randomized controlled trials. (2024) pubmed
- The Effects of Bitter Melon ( Mormordica charantia ) on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2024) pubmed
- Multidimensional Uses of Bitter Melon (Momordica charantia L.) Considering the Important Functions of its Chemical Components. (2025) pubmed